PMID- 26900815
OWN - NLM
STAT- MEDLINE
DCOM- 20160829
LR  - 20201218
IS  - 1532-0979 (Electronic)
IS  - 0147-5185 (Linking)
VI  - 40
IP  - 5
DP  - 2016 May
TI  - BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and 
      Desmoplastic Mesotheliomas.
PG  - 714-8
LID - 10.1097/PAS.0000000000000616 [doi]
AB  - The separation of sarcomatous and desmoplastic mesotheliomas from benign 
      organizing pleuritis can be morphologically very difficult. Deletion of p16 
      (CDKN2A) by fluorescence in situ hybridization (FISH) testing appears to be a 
      reliable marker of malignancy in mesothelial proliferations, and more recently it 
      has been reported that, in this setting, loss of BAP1 by immunohistochemistry is 
      only seen in malignant mesotheliomas. To determine how useful these tests are 
      with sarcomatous and desmoplastic mesotheliomas, we examined 20 such tumors. Loss 
      of BAP1 was seen in 3/20 (15%) and deletion of p16 by FISH was seen in 16/20 
      (80%) cases. Loss of one or the other marker was observed in 17/20 (85%). We also 
      examined 13 sarcomatoid carcinomas, an important differential diagnosis of 
      sarcomatoid mesotheliomas, and found that BAP1 was never lost, but p16 was 
      deleted in 3/11 (27%). We conclude that: (1) BAP1 immunohistochemistry is 
      relatively insensitive in the context of sarcomatous and desmoplastic 
      mesotheliomas, but as a matter of time and cost efficiency may nonetheless be a 
      useful first approach to the problem; (2) deletion of p16 by FISH is considerably 
      more sensitive, but there remain a proportion of cases in which p16 is not 
      deleted; (3) a small improvement in sensitivity can be achieved by using both 
      markers; (4) in the context of a spindle cell malignant tumor in the pleura or 
      peritoneum, which morphologically might be a metastatic sarcomatoid carcinoma or 
      a mesothelioma, the finding of BAP1 loss favors mesothelioma, but p16 FISH cannot 
      be used to separate sarcomatous mesotheliomas from sarcomatoid carcinomas.
FAU - Hwang, Harry C
AU  - Hwang HC
AD  - *PhenoPath Laboratories, Seattle, WA daggerDepartment of Pathology, Vancouver General 
      Hospital, University of British Columbia, Vancouver, BC, Canada.
FAU - Pyott, Shawna
AU  - Pyott S
FAU - Rodriguez, Stephanie
AU  - Rodriguez S
FAU - Cindric, Ashlie
AU  - Cindric A
FAU - Carr, April
AU  - Carr A
FAU - Michelsen, Carmen
AU  - Michelsen C
FAU - Thompson, Kim
AU  - Thompson K
FAU - Tse, Christopher H
AU  - Tse CH
FAU - Gown, Allen M
AU  - Gown AM
FAU - Churg, Andrew
AU  - Churg A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Surg Pathol
JT  - The American journal of surgical pathology
JID - 7707904
RN  - 0 (BAP1 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 3.4.19.12 (Ubiquitin Thiolesterase)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Biomarkers, Tumor/analysis/genetics
MH  - Biopsy
MH  - Cyclin-Dependent Kinase Inhibitor p16/*genetics
MH  - Diagnosis, Differential
MH  - Female
MH  - Gene Deletion
MH  - Humans
MH  - *Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*diagnosis/enzymology/genetics/pathology
MH  - Male
MH  - Mesothelioma/*diagnosis/enzymology/genetics/pathology
MH  - Mesothelioma, Malignant
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Sarcoma/*diagnosis/enzymology/genetics/pathology
MH  - Tumor Suppressor Proteins/*analysis
MH  - Ubiquitin Thiolesterase/*analysis
EDAT- 2016/02/24 06:00
MHDA- 2016/08/30 06:00
CRDT- 2016/02/23 06:00
PHST- 2016/02/23 06:00 [entrez]
PHST- 2016/02/24 06:00 [pubmed]
PHST- 2016/08/30 06:00 [medline]
AID - 10.1097/PAS.0000000000000616 [doi]
PST - ppublish
SO  - Am J Surg Pathol. 2016 May;40(5):714-8. doi: 10.1097/PAS.0000000000000616.